Skip to main content
Signal8

Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

$IRONPress releaseJun 2, 2026, 8:00 AM ETRead the release

Disc Medicine presented updated positive Phase 2 data for DISC-0974 in myelofibrosis-associated anemia at the ASCO Annual Meeting. The trial showed durable anemia responses across all patient subgroups, including those receiving concomitant JAK inhibitor therapy, with >75% hepcidin reduction and significant improvements in transfusion burden and fatigue. Major response rates ranged from 50% to 64% depending on baseline transfusion status, supporting the drug's potential in a broad patient population with substantial unmet need.

Key figures

Drug Name
DISC-0974
Phase Of Trial
Phase 2
Total enrolled
61
Hepcidin reduction
>75%
Responder analysis n
50
N TD major response rate
55%
N TD overall response rate
68%
TD Low overall response rate
73%
TD High overall response rate
88%
JAK inhibitor major response rate
56%
JAK inhibitor overall response rate
72%
TD Low transfusion independence rate
64%
TD High transfusion independence rate
50%

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.